ATC Group: L01BB Purine analogues

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01BB in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01B Antimetabolites
4 L01BB Purine analogues

Group L01BB contents

Code Title
L01BB02 Mercaptopurine
L01BB03 Tioguanine
L01BB04 Cladribine
L01BB05 Fludarabine
L01BB06 Clofarabine
L01BB07 Nelarabine

Active ingredients in L01BB

Active Ingredient

Cladribine is a nucleoside analogue of deoxyadenosine. In resting cells cladribine causes DNA single-strand breaks, rapid nicotinamide adenine dinucleotide consumption, ATP depletion and cell death.

Clofarabine is a purine nucleoside anti-metabolite. Its antitumour activity is believed to be due to 3 mechanisms. Clofarabine produces DNA polymerase inhibition resulting in termination of DNA chain elongation and/or DNA synthesis/repair and ribonucleotide reductase inhibition with reduction of cellular deoxynucleotide triphosphate (dNTP) pools. Clofarabine also produces disruption of mitochondrial membrane integrity with the release of cytochrome C and other proapoptotic factors leading to programmed cell death even in non-dividing lymphocytes.

Fludarabine is a water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine 9-β-D-arabinofuranosyladenine (ara-A) that is relatively resistant to deamination by adenosine deaminase. Fludarabine phosphate is rapidly dephosphorylated to 2F-ara-A which is taken up by cells and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2F-ara-ATP. This metabolite has been shown to inhibit ribonucleotide reductase, DNA polymerase α/δ and ε, DNA primase and DNA ligase thereby inhibiting DNA synthesis.

Mercaptopurine is an inactive pro-drug which acts as a purine antagonist but requires cellular uptake and intracellular anabolism to thioguanine nucleotides for cytotoxicity. The mercaptopurine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. The thioguanine nucleotides are also incorporated into nucleic acids and this contributes to the cytotoxic effects of the active substance.

Nelarabine is a pro-drug of the deoxyguanosine analogue ara-G. Accumulation of ara-GTP in leukaemic blasts allows for preferential incorporation of ara-GTP into deoxyribonucleic acid (DNA) leading to inhibition of DNA synthesis. This results in cell death. Other mechanisms may contribute to the cytotoxic effects of nelarabine. In vitro, T-cells are more sensitive than B-cells to the cytotoxic effects of nelarabine.

Tioguanine is a sulphydryl analogue of guanine and behaves as a purine antimetabolite. It is activated to its nucleotide, thioguanylic acid. Tioguanine metabolites inhibit de novo purine synthesis and purine nucleotide interconversions. Tioguanine is also incorporated into nucleic acids and DNA (deoxyribonucleic acid) incorporation is claimed to contribute to the agent’s cytotoxicity.

Related product monographs

Document Type Information Source  
 ATRIANCE Solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 CLOLAR Solution for injection MPI, US: SPL/PLR FDA, National Drug Code (US)
 Evoltra 1mg/ml concentrate for solution for infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 EVOLTRA Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 FLUDARA Film-coated tablets MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FLUDARA Powder for solution for injection or infusion MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 HANIXOL Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 IVOZALL Concentrate for solution for infusion MPI, EU: SmPC European Medicines Agency (EU)
 LANVIS MPI, EU: SmPC Health Products Regulatory Authority (IE)
 LITAK Solution for injection MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 MAVENCLAD Tablet MPI, EU: SmPC European Medicines Agency (EU)
 PURI-NETHOL Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 XALUPRINE Oral suspension MPI, EU: SmPC European Medicines Agency (EU)